← All trials
NCT01131195
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jul 19, 2010
- Primary completion
- Dec 14, 2012
- Completion date
- Jun 30, 2019
- First posted
- —
- Last posted
- —
- Enrollment
- 142
- Arms / groups
- 2 / —
- Source
- AACT · pre-existing
Sponsors
- Swiss Group for Clinical Cancer ResearchLead sponsor
- Luzerner KantonsspitalStudy chair
- University of BaselStudy chair
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.